Comparative Pharmacology
Head-to-head clinical analysis: CORTEF versus PREDAIR FORTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTEF versus PREDAIR FORTE.
CORTEF vs PREDAIR FORTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to the glucocorticoid receptor, leading to altered gene expression and inhibition of inflammatory mediators such as prostaglandins and leukotrienes.
Prednisolone is a glucocorticoid that binds to the glucocorticoid receptor, altering gene expression to produce anti-inflammatory and immunosuppressive effects.
Hydrocortisone (Cortef) 10-30 mg orally 2-4 times daily; for anti-inflammatory effect: 20-240 mg orally daily in divided doses; for physiologic replacement: 20-30 mg orally daily in divided doses (e.g., 10 mg morning, 5 mg afternoon).
0.5-1.5 mL (5-15 mg prednisolone equivalent) injected subconjunctivally or peribulbarly as a single dose; may repeat weekly if needed. For systemic use, 5-60 mg/day oral prednisolone equivalent, divided 1-2 times daily.
None Documented
None Documented
Plasma terminal half-life: 1.5–2.5 hours (cortisol); duration of action: 8–12 hours due to intracellular effects.
The terminal elimination half-life of prednisolone is approximately 2-4 hours in adults. In children, the half-life may be shorter (1-3 hours). The half-life can be prolonged in patients with hepatic impairment or severe renal disease. This short half-life allows for alternate-day dosing to minimize hypothalamic-pituitary-adrenal (HPA) axis suppression.
Renal (primarily as inactive metabolites, <5% unchanged); biliary/fecal (minor).
Prednisolone (active metabolite of prednisone) is eliminated primarily via renal excretion of inactive metabolites (approximately 80-90%) and to a minor extent via fecal excretion (approximately 10-20%). Less than 1% of the dose is excreted unchanged in urine.
Category C
Category C
Systemic Corticosteroid
Systemic Corticosteroid